Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor
{{output}}
Tumor hypoxia is associated with therapy resistance and poor patient prognosis. Hypoxia-activated prodrugs, designed to selectively target hypoxic cells while sparing normal tissue, represent a promising treatment strategy. We report the pre-clinical efficacy ... ...